SEC Filing Summary: Amedica Corporation (8-K)
Business Context and Reporting Period
This Form 8-K was filed by Amedica Corporation on November 21, 2014, reporting events occurring on November 20, 2014. The filing details the entry into a material definitive agreement for an underwritten public offering of units. Note: While the request metadata references "Sintx Technologies, Inc.", the filing text explicitly identifies the registrant as Amedica Corporation.
Key Financial Metrics and Offering Details
- Gross Proceeds: Approximately $13.0 million.
- Net Proceeds: Approximately $11.6 million (after underwriting discounts, commissions, and estimated expenses).
- Units Offered: 11,441,646 units at a public offering price of $1.14 per unit.
- Unit Composition: One share of common stock and one warrant to purchase one share of common stock.
- Over-Allotment Option: Underwriters granted a 45-day option to purchase up to 1,716,246 additional shares and/or warrants (15% of the primary offering).
- Warrant Terms: Exercise price of $1.48 per share (130% of public offering price); exercisable immediately; expire five years from issuance.
- Unit Purchase Options: Underwriters granted options to purchase up to 572,082 units at $1.425 per unit (125% of public offering price).
The filing does not provide current revenue, profit, cash flow, margin, or debt figures for the company.
Material Changes and Unusual Items
The primary material change is the capital raise via the public offering. The filing does not report changes in operating performance compared to a prior period. Unusual items include specific warrant exercise mechanisms:
- Cashless Exercise: After 120 days, holders may elect a cash payment based on Black-Scholes value or a cashless exercise formula.
- Mandatory Exercise: If the stock trades 25% or more above the exercise price for 20 consecutive trading days (after 120 days), the company may require cash exercise.
- Lock-Up: Unit Purchase Options and resulting shares are subject to an 180-day lock-up period.
Guidance, Outlook, and Risks
The offering is expected to close on or about November 26, 2014, subject to customary closing conditions. The filing includes standard risk disclosures regarding the underwriting agreement, noting that representations and warranties are for the benefit of the contracting parties and may not reflect the actual state of facts for investors. There is no established public trading market for the warrants, and the company does not intend to list them on any exchange.
Key Facts for Investor Verification
- Verify the actual closing date of the offering (expected November 26, 2014) and the final net proceeds received.
- Confirm whether the over-allotment option was exercised by the underwriters.
- Review the company's use of proceeds as detailed in the related Form S-1 (File No. 333-199753).
- Monitor the stock price relative to the $1.48 warrant exercise price to assess the likelihood of mandatory exercise provisions being triggered.
- Check for any subsequent filings regarding the listing status of the warrants or changes in the company's capital structure.